Select Page
Responsive Centered YouTube Video
Investigation into abnormal clotting in live patients raises concerns and prompts scientific inquiry.
  • Discussion initiated in April 2023 on abnormal clotting in live patients. 0:36

  • Anonymously shared observations of abnormal clotting in live patients sparked further interest. 2:01

  • Scientists from South Africa and the USA are actively researching abnormal clotting phenomena. 3:00

  • Live clots extracted from patients revealed shocking sizes and implications for survival. 5:08

  • Challenges in degrading massive clots and treatment strategies discussed. 6:40

Investigation into spontaneous formation of microclots in COVID-19 patients and potential implications.
  • Study on microclots formation in COVID-19 patients began in 2020. 7:26

  • Discovery of amalo clots forming spontaneously without thrombin in lab. 9:35

  • Amalo clots identified in blood samples of COVID-19 patients. 10:09

  • Attempt to induce similar clots in healthy blood using Spike protein. 10:26

  • Association of microclots with long COVID symptoms. 10:45

  • Research paper review on characteristics and dangers of microclots. 11:03

  • Explanation of fibrin clot formation and breakdown process. 11:46

  • Focus on understanding differences in amalo clots within the clotting Cascade. 12:11

Formation of abnormal blood clots in COVID patients due to interactions of inflammatory molecules and spike proteins.
  • Soluble fibrinogen converted to insoluble microclots in response to inflammatory markers and spike protein. 12:21

  • Microclots can lead to macroclots in some patients with long COVID or spike injury. 17:26

Discussion on the formation of microclots, biomarkers, and potential diagnostic tools for identifying different types of clots.
  • Microclots detected in thrombitesting raise concerns and are correlated with biomarkers like TGF beta 1. 18:03

  • Elevated D-dimer levels may indicate breakdown of clots, suggesting a need for better clot qualification methods. 18:11

  • Presence of fibrous clots resembling amyloid formation observed in living individuals challenges previous postmortem assumptions. 20:06

  • Different stages of clot formation shown in images, with stage four indicating significant microclot accumulation. 21:06

  • Macroclots attaching to endothelial cells may exhibit amyloid characteristics, impacting clinical detection methods. 21:51

  • Microclots can pass through capillaries without fully blocking blood flow, suggesting unique structural properties. 22:53

Discussion on the formation of significant macro clots and the role of D dier in understanding clot breakdown processes.
  • Significant macro clots pulled from healthy individuals may trap microclots, indicating a possible gradual clot formation process. 23:44

  • D dier is found to be elevated in many patients, suggesting a potential mix of clot types transitioning to fully insoluble clots. 27:07

  • The body’s fibrolytic system may not be critically failed in individuals with severe long Co, as they are still alive. 28:38

Discussion on unusual blood clots found in live individuals and the need for further research and awareness.
  • Unusual blood clots observed in live individuals are concerning 28:45

  • Need for investigating blood work and inflammatory panels of affected individuals 29:10

  • Lack of scientific discussion and research on the phenomenon 29:42

  • Surprise at the lack of awareness and investigation among medical professionals 30:26

  • Questioning the occurrence of massive clots before exposure to Spike protein 33:24

  • Physical characteristics of clots seem to have changed, affecting their breakdown 33:53

Discussion on potential sources of Spike protein triggering clot formation in individuals post-vaccination or infection.
  • Healthy individuals may also have underlying conditions predisposing them to clot formation. 34:18

  • Spike protein from various sources, including vaccination and persistent infection, could contribute to clotting. 35:10

  • Study in progress to evaluate microclots in individuals with post-vaccine events like pericarditis. 36:30

  • Concerns raised about ongoing exosome transfer of Spike proteins leading to prolonged inflammation and coagulation. 39:05

  • Evidence of circulating Spike protein in vaccinated individuals months after vaccination. 39:28

Discussion on potential mechanisms of clot formation in relation to Spike protein exposure.
  • Spike protein, from the virus or vaccine, acts as a magnet for every cell it comes in contact with. 39:53

  • Importance of identifying individuals at risk for adverse effects from Spike protein exposure. 40:21

  • Need for a balanced approach in medicine considering risk, benefits, and alternatives of interventions. 40:29

  • Emphasis on the necessity of diagnostics, such as flow cytometry, for accurate assessment and treatment initiation. 41:31

  • Appreciation for clinicians and researchers working towards proactive patient care in the face of emerging health challenges. 42:25

  • Acknowledgment of the role of endothelitis and microparticle clotting in affecting various body systems. 43:27

  • Recognition of vascular and neuroinflammation as potential consequences of clotting and endothelial damage. 43:40

  • Development of natural compounds to reverse clotting and mitigate risks of complications. 43:53

Exploration of alternative treatments for a unique disease, importance of scientific research, and ongoing work in South Africa.
  • Exploring safer and effective alternatives for treatment 44:29

  • Importance of thinking outside the box for a massive disease 44:41

  • Significance of ongoing scientific research globally 45:28

  • Supporting scientists financially for crucial research 45:44

  • Simple method to check for amalo f fibrin microts 46:00

  • Continued discussions and future plans for research 46:14